Clinical Focus
Advertisement
Advertisement
Trending on Modern Retina
1
Merck launches phase 2b/3 MALBEC trial of MK-8748 in wet AMD
2
FDA grants RMAT designation to RTx-015 optogenetic gene therapy for retinitis pigmentosa
3
FDA approves extended dosing intervals up to 20 weeks for EYLEA HD in wAMD and DME
4